Heme-STAMP Minimal Residual Disease

ORDER CODE: HSTAMPMRD

ORDERING

SPECIMEN

PROCESSING

RESULTS

Test Code

SHC TEST CODE LPCH TEST CODE
LABHSTAMPMRD LABHSTAMPMRD

Specialty

Hematopathology

Synonyms

Myeloid, heme panel, Myeloid/Lymphoid panel, Heme Stamp, fusion, translocation

Clinical Utility

This assay detects single nucleotide variants (SNVs), short insertion-deletions and selected gene fusions in 164 genes recurrently altered in myeloid and lymphoid neoplasms. The Stanford Actionable Mutation Panel for Hematopoietic and Lymphoid Malignancies (Heme-STAMP) is a targeted next generation sequencing method. The workflow includes acoustic shearing of isolated genomic DNA, followed by efficient preparation of sequencing libraries and a targeted enrichment approach to capture genomic regions of interest. The enrichment is accomplished using custom designed libraries of capture oligonucleotides that target a specific set of genomic regions. This panel targets 164 genes, either in part or fully, with the genes selected on the basis of their known impact as actionable targets of existing and emerging anti-cancer therapies, their prognostic features, and/or their mutation recurrence frequency across patients with hematopoietic neoplasms. These genomic features are interrogated to achieve a minimum analytic detection-limit of 5% for SNVs and insertion-deletion variants. Pooled libraries are sequenced on an Illumina sequencing instrument.

Due to inherent limitations of the NGS method, insertion-deletion variants larger than 25 bp are not reliably detected. To detect larger insertion and deletions in key regions of CALR and FLT3, PCR amplification of these regions is performed, followed by capillary electrophoresis fragment analysis.

CPT Code

81455
Preferred Specimen Type
Whole blood, Bone Marrow Aspirate, FFPE tissue
Container Type
Lavender top tube (EDTA) or FFPE for tissue
Container Image 1

Specimen Quantity and Stability

Special Handling

Peripheral blood and bone marrow aspirate should be shipped refrigerated.

Department

Molecular Pathology

Standard Run Time(s)

Weekly

Turnaround Time

ROUTINE STAT
28 days 28 days

Methodology

Next Generation Sequencing (NGS)

Interpretation

The list of targeted genes can be found at the URL below: https://stanfordlab.com/content/dam/stanfordlabs/pdfs/Heme-STAMP_infosheet.pdf

Test Code

SHC TEST CODE LPCH TEST CODE
LABHSTAMPMRD LABHSTAMPMRD

Specialty

Hematopathology

Synonyms

Myeloid, heme panel, Myeloid/Lymphoid panel, Heme Stamp, fusion, translocation

Clinical Utility

This assay detects single nucleotide variants (SNVs), short insertion-deletions and selected gene fusions in 164 genes recurrently altered in myeloid and lymphoid neoplasms. The Stanford Actionable Mutation Panel for Hematopoietic and Lymphoid Malignancies (Heme-STAMP) is a targeted next generation sequencing method. The workflow includes acoustic shearing of isolated genomic DNA, followed by efficient preparation of sequencing libraries and a targeted enrichment approach to capture genomic regions of interest. The enrichment is accomplished using custom designed libraries of capture oligonucleotides that target a specific set of genomic regions. This panel targets 164 genes, either in part or fully, with the genes selected on the basis of their known impact as actionable targets of existing and emerging anti-cancer therapies, their prognostic features, and/or their mutation recurrence frequency across patients with hematopoietic neoplasms. These genomic features are interrogated to achieve a minimum analytic detection-limit of 5% for SNVs and insertion-deletion variants. Pooled libraries are sequenced on an Illumina sequencing instrument.

Due to inherent limitations of the NGS method, insertion-deletion variants larger than 25 bp are not reliably detected. To detect larger insertion and deletions in key regions of CALR and FLT3, PCR amplification of these regions is performed, followed by capillary electrophoresis fragment analysis.

CPT Code

81455

close ORDERING
Preferred Specimen Type
Whole blood, Bone Marrow Aspirate, FFPE tissue
Container Type
Lavender top tube (EDTA) or FFPE for tissue
Container Image 1

Specimen Quantity and Stability

Special Handling

Peripheral blood and bone marrow aspirate should be shipped refrigerated.


close SPECIMEN

Department

Molecular Pathology

Standard Run Time(s)

Weekly

Turnaround Time

ROUTINE STAT
28 days 28 days

close PROCESSING

Methodology

Next Generation Sequencing (NGS)

Interpretation

The list of targeted genes can be found at the URL below: https://stanfordlab.com/content/dam/stanfordlabs/pdfs/Heme-STAMP_infosheet.pdf


close RESULTS